1067902-51-5

Upstream product

• 391212-29-6 O-(2-vinyloxyethyl)hydroxylamine 
• 934639-05-1 4-(4-bromo-2-fluorophenylamino)-1,5-dimethyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid 
• 869357-55-1 4-chloro-1,5-dimethyl-6-oxopyridazine-3-carboxylic acid 
• 869357-54-0 4-hydroxy-1,5-dimethyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid 
• 869357-46-0 diethyl 2-(2-methyl-2-propionylhydrazono)malonate 

Relevant academic research and scientific papers

COMBINATION OF A MEK- INHIBITOR AND A B-RAF INHIBITOR FOR THE TREATMENT OF CANCER

This invention relates to a combination product comprising a MEK inhibitor and a B-raf inhibitor, and to methods for the production of an anti-cancer effect in a patient, which is accordingly useful in the treatment of cancer in a patient. More specifically the present invention relates to: a combination product comprising a MEK inhibitor and a B raf inhibitor; a combination product comprising a kit of parts comprising a MEK inhibitor and a B-raf inhibitor; use of the combination product in the treatment of cancer; a method of treating cancer comprising administering the combination product to a patient. The combination product and methods of the invention are also useful in the treatment of other diseases associated with the activity of MEK, and/or B-raf.

HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF

Disclosed are MEK inhibitors useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.